Dr. Maurie Markman comments on a study in Lancet Oncology indicating that patients with NSCLC patients who have an EGFR mutation benefit more from gefitinib than from cisplatin/docetaxel. Medscape Genomic Medicine
An FDA review launched in the wake of a controversial 2010 meta-analysis has concluded that the drugs do not pose a cancer risk to patients. The FDA says it conducted a much larger, more comprehensive review of the data to reach its reassuring conclusions. Not everyone, however, is satisfied. br / iHeartwire/i
Major cancer organizations are stepping up the pressure to bring attention to the global cancer crisis and call on world leaders to attend the upcoming UN summit on noncommunicable diseases. br / iMedscape Medical News/i
Those with prostate cancer and high metastatic risk benefit from 3 years of hormone therapy, plus radiation. So why are doctors recommending a shorter duration? Dr. Gerald Chodak explores the issues. Medscape Urology
